Reuters logo
7 months ago
BRIEF-Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers
December 12, 2016 / 12:23 PM / 7 months ago

BRIEF-Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers

1 Min Read

Dec 12 (Reuters) - Immunomedics Inc

* Immunomedics announces novel immuno-oncology program targeting Trop-2-expressing cancers

* Completing enrollment of 100 TNBC patients into ongoing phase 2 clinical trial of IMMU-132 by year-end 2016

* Immunomedics - submitting a biological license application to FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017

* Immunomedics - presenting interim results of phase 2 clinical trials for patients with urothelial cancer at a symposium on genitourinary cancers to be held in early 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below